Why the study?
Does ICRF-187 prevent doxorubicin-induced cardiac toxicity in women with advanced breast cancer receiving FDC chemotherapy?
Does ICRF-187 prevent doxorubicin-induced cardiac toxicity in women with advanced breast cancer receiving FDC chemotherapy?
ICRF-187 provides significant protection against doxorubicin-induced cardiac toxicity in women with advanced breast cancer without compromising antitumor efficacy.
No takes yet. Share an insight, caveat, or question.
Supports ICRF-187 for doxorubicin cardiotoxicity prevention in advanced breast cancer; confirms animal data in RCT.
Speyer et al. (1988) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: